Peijia Medical Limited

Equities

9996

KYG6981F1090

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
3.66 HKD -3.94% Intraday chart for Peijia Medical Limited -.--% -50.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JenaValve Technology, Inc. announced that it has received $100.4 million in funding from a group of investors CI
Peijia Medical Limited Delays in Publication of 2023 Annual Results CI
Peijia Medical Narrows 2023 Loss as Revenue Jumps 76% MT
Peijia Medical Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial CI
Peijia Medical's 2023 Profit to Jump Up to 79.4% MT
Peijia Medical Limited Announces Unaudited Revenue Results for the Year Ended December 31, 2023 CI
Peijia Medical's Stock Jumps on Positive Updates For Two Devices MT
Peijia Medical Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Peijia Medical Enrolls First Patient in TaurusTrio Transcatheter System; Shares Up 4% MT
Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio?? Transcatheter Aortic Valve Replacement System in China CI
Peijia Medical's H1 Revenue Rises By Up to 94% MT
Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023 CI
China Approves Peijia Medical Unit's Micro Guidewire for Neuro-Intervention Operations MT
Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire CI
Peijia Medical Completes Two Commercial Implants with Trilogy System in Hong Kong MT
Peijia Medical's 2022 Loss Narrows 29% MT
Peijia Medical Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Peijia Medical's 2022 Revenue Surges Up to 90.4% MT
Peijia Medical Limited Reports Unaudited Operating Statistics for the Year Ended December 31, 2022 CI
Peijia Medical Enrolls First Patient in Transcatheter Repair System Clinical Trial in China MT
Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China CI
Peijia Medical Completes First Patient Implant in Transcatheter Tricuspid Valve Replacement System Trial MT
Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World CI
Peijia Medical Enrolls First Patient in China Clinical Trial for Mitral Valve Replacement; Shares Climb 4% MT
Chart Peijia Medical Limited
More charts
Peijia Medical Ltd is a China-based holding company mainly engaged in the research and development of interventional procedural medical devices. Through its subsidiaries, the Company operates two segments. Transcatheter Valve Therapeutic Business segment is mainly engaged in the development of transcatheter valve therapeutic medical devices. Neurointerventional Business segment is engaged in the research and development of neurointerventional procedural medical devices. The Company's main products under development include TaurusOne, TaurusElite, TaurusNXT and others. The Company operates its businesses primarily in domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.38 CNY
Average target price
11.8 CNY
Spread / Average Target
+249.22%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 9996 Stock
  4. News Peijia Medical Limited
  5. Peijia Medical : Eyes Shanghai Listing; Shares Jump 6%